The Rebus Esper leverages the company's patented synthetic aperture optics technology, which enables the quantitative analysis of tens of millions of cellular features across hundreds of thousands of cells. The fully integrated, automatic instrument delivers high-throughput, quantitative, single-molecule, single-cell data with spatial context and subcellular resolution, according to the company.

The company is also releasing the Esper high fidelity assay, its first assay for the platform. It is an ultrasensitive assay that is based on cyclic single-molecule fluorescent in situ hybridization (smFISH) chemistry, which can resolve and map individual RNA molecules in their original locations, giving expression levels for up to 30 custom genes.

Rebus plans to rapidly expand the assay menu for the Rebus Esper platform, including offering an expanded suite of high fidelity assays to enable a higher level of multiplexing and protein co-detection. The company will also develop assays enabling multiplex gene expression in formalin-fixed, paraffin embedded (FFPE) samples and the simultaneous analysis of over 1000 genes.

Rebus is launching the instrument at the Advances in Genome Biology and Technology (AGBT) 2021 General Meeting.

Vizgen debuts accelerator lab in the U.S.
Life sciences company Vizgen has established an accelerator lab in the U.S. to advance pharmaceutical research and development.